Results

Total Results: 2,078 records

Showing results for "drugs".

61. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/dementia_hi_impact.pdf
    January 01, 2012 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … interventions expected to be within 0 to 4 years of potential diffusion (e.g., in phase III trials for pharmaceuticals … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … The search is on for ways to definitively diagnose AD and for drugs, biologics, and alternative or

62. Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics – Update | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/atypical-antipsychotics-off-label-update/research-protocol
    May 19, 2010 - These drugs have been studied for off-label use in several conditions. … 84 published studies on atypical antipsychotics and found that the most common off-label uses of the drugs … Sub-Question 2: How do atypical antipsychotic medications compare with other drugs, including first … How do they compare within the class and with other drugs used for the conditions? … across condition, and then compared within the class and with other drugs used for the conditions.

63. PEPTIC ULCER #11 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1412.pdf
    December 01, 2014 - NPS Pharmaceuticals, Inc.. … Bedminster (NJ): NPS Pharmaceuticals, Inc.; 2014 Jun. 18 p. 8. … Bedminster (NJ): NPS Pharmaceuticals, Inc.; 2011 May 12 [accessed 2011 Jul 15]. [2 p]. … Bedminster (NJ): NPS Pharmaceuticals, Inc.; 2011 Oct 31 [accessed 2011 Nov 11]. [4 p]. … Bedminster (NJ): NPS Pharmaceuticals, Inc.; 2012 Dec 21. 45 p. 14.

64. S9 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s9.pdf
    October 01, 2007 - detailed (including beneficiary identifiers, contract identifiers pharmacy provider infor- mation on drugs … Key Words: Medicare, Part D, pharmaceuticals (Med Care 2007;45: S9–S12) The Medicare Part D benefit … Part D plan covers 15%, and the beneficiary pays a 5% coinsurance, or copayments of $2 for generic drugs … and $5 for nongeneric drugs. … Drugs provided (including the National Drug Classifica- tion �NDC� code, compound code, and quantity

65. Nonopioid Pharmacologic Treatments for Chronic Pain: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-summary.pdf
    April 01, 2020 - for Chronic Pain: Evidence Summary Purpose of Review Evaluate the benefits and harms of nonopioid drugs … neuropathy/post-herpetic neuralgia and fibromyalgia, and small with nonsteroidal anti-inflammatory drugs … (NSAIDs), acetaminophen, topical formulations such as capsaicin, and drugs used for other conditions … Few differences were found between drugs. … Differences were not found between drugs or doses.

66. Topic Suggestion Description | Effective Health Care Program
    effectivehealthcare.ahrq.gov/get-involved/nominated-topics/the-american-college-of-chest-physicians-accp-proposes-to-update-the-medical-therapies-section-of-2007-updated-publication-on-medical-therapies-for-pulmonary-arterial-hypertension-accp-evidence-based-clinical-practice-guideli
    January 01, 2007 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to … see compared: 2 new drugs have now been approved for the treatment of PAH: inhaled treprostinil … ambrisentan Comparisons should be made between these new drugs and the older ones, listed here by … Side effects of various drugs include but are not limited to liver function abnormalities, elevated serum … Since the 2007 update of the medical therapies section of the 2004 guidelines, 2 new drugs have been

67. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-2007_executive.pdf
    January 01, 2007 - Available therapies for RA include corticosteroids; synthetic disease-modifying antirheumatic drugs, … Finally, very little is known about the benefits or risks of these drugs in different patient subgroups … : comparative risk of harms: infliximab) vs. anti-TNF Moderate Low drugs Biologic DMARDs vs. … Moderate Moderate In patients with no previous use of study drugs, higher ACR 20/50 response rates … Adjusted indirect comparisons also indicated that anakinra has lower efficacy than anti-TNF drugs.

68. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Available: http://www.cesar.umd.edu/cesar/drugs/ketamine. pdf. 4. … CNS Drugs. 2012 Mar 1;26(3):189-204. … http://www.cesar.umd.edu/cesar/drugs/ketamine.pdf http://www.cesar.umd.edu/cesar/drugs/ketamine.pdf http … Rochester (MI): JHP Pharmaceuticals, LLC; 2011 Jun. 4 p.

69. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/06_devdelays_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … In the health care sector, horizon scanning pertains to identifying new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … These drugs will probably face intense scrutiny, considering the challenges of accurately diagnosing

70. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
    October 01, 2015 - Boston (MA): Vertex Pharmaceuticals, Inc.; 2014 Nov 05 [accessed 2014 Dec 11]. [3 p]. … Boston (MA): Vertex Pharmaceuticals Inc.; 2015 Jan 11 [accessed 2015 May 13]. [5 p]. … Boston (MA): Vertex Pharmaceuticals Inc.; 2015 May 12 [accessed 2015 May 13]. [2 p]. … Boehringer Ingelheim Pharmaceuticals, Inc. … Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc.; 2014 Oct. 18 p.

71. DEcIDE 32: The Incident User Design in Comparative Effectiveness Research (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/incident-user-design_research.pdf
    May 01, 2012 - ...............................................................................3 Recently Marketed Drugs … If newer drugs were started more recently, the newer drugs may appear safer than older drugs because … their apparent rate would be lower; investigators would observe a higher event rate for older drugs … in a class; requiring all patients in the cohort to have a 365-day window without use of any drugs … For drugs that are available as combination products, it is important to handle the baseline period

72. Dietary-Supplements Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
    April 01, 2012 - Comparative Effectiveness Review Number 51 Dietary Supplements in Adults Taking Cardiovascular Drugs … (when compared with cardiovascular drugs alone or cardiovascular drugs and a different dietary supplement … • Studies included cardiovascular drugs not marketed in the United States. … Drugs Aging. 2009 Dec;26(Suppl 1):41-51. PMID: 20136168. 13. Garner JB. … Dietary Supplements in Adults Taking Cardiovascular Drugs.

73. #14 SUBSTANCE ABUSE (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/14_substanceabuse_potential_high_impact_june_2012.pdf
    January 01, 2012 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … However, experts shared the belief that these drugs’ benefits would prove to be only incremental … Prescription drugs: abuse and addiction. [internet].

74. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_executive.pdf
    September 01, 2011 - Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) … Treatment with the class of agents known as disease-modifying anti- rheumatic drugs (DMARDs) has become … , which are created by biologic processes, or non-biologic drugs, which are manufactured chemically. … Furthermore, it is possible that the effectiveness of these drugs varies by category of JIA. … be used for difficult-to-treat JIA, or the impact of using multiple drugs.

75. The Incident User Design in Comparative Effectiveness Research | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/incident-user-design/research
    May 15, 2012 - coronary heart disease events among patients using COX-2 selective non-steroidal anti-inflammatory drugs … For older drugs, a 365-day window may identify patients starting a new episode of therapy, but not … Most of these patients used other disease-modifying antirheumatic drugs (DMARDs) and have now switched … If newer drugs were started more recently, the newer drugs may appear safer than older drugs because … COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

76. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-prevention_research-protocol.pdf
    November 03, 2011 - The FDA has approved no drugs for migraine prevention in children. … prevention, which include novel antiepileptic drugs, calcium channel modulators, glutamate blockers … o Use of drugs for acute migraine (prescribed or over-counter). … Drugs approved by the FDA for migraine prevention and off-label drugs examined in clinical trials. … Studies that examined eligible drugs on populations with other diseases.

77. S29 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s29.pdf
    October 01, 2007 - it involved 2 short-term drugs instead of 2 long-term drugs? … Changes could also confuse physicians; confusion could generalize beyond the study drugs. … Some leaders noted that newer drugs are not typically included on their formulary. … Including short term drugs would be more challenging. … Make clear that physicians have flexibility to prescribe nonstudy drugs.

78. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/it-architecture-for-post-marketing-surveillance-arizona-cert.pdf
    September 01, 2007 - For example, although 15 drugs were withdrawn from the market between 1997 and 2005 based on MedWatch … The surveillance administration process involves the identification of newly introduced drugs that … No effective mechanism currently exists for tracking the purchase of such drugs. … Such dispensation of drugs by the physicians may need to be monitored, especially for drugs that have … In order to cater to this need, all drugs taken by patients will need to be monitored.

79. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicine-safety-call-center_research.pdf
    September 01, 2007 - For example, although 15 drugs were withdrawn from the market between 1997 and 2005 based on MedWatch … The surveillance administration process involves the identification of newly introduced drugs that … No effective mechanism currently exists for tracking the purchase of such drugs. … Such dispensation of drugs by the physicians may need to be monitored, especially for drugs that have … In order to cater to this need, all drugs taken by patients will need to be monitored.

80. Evidence Summary for CER 239: Acute Treatments for Episodic Migraine (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-239-acute-migraine-evidence-summary.pdf
    December 01, 2020 - Points • Compared with placebo, treatments such as triptans, NSAIDs (nonsteroidal anti- inflammatory drugs … Some opioids may be less effective than other drugs. … Results Evidence on triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was summarized from … In terms of applicability, several of the established drugs, such as the ergot alkaloids, may not be … In general, adverse events of these drugs are mild and transient.